复方阿胶浆改善化疗后骨髓抑制的临床疗效观察  

Clinical effect on compound Ejiao Jiang treating chemotherapy-induced myelosuppression

作　　者：宋腾[1] 梁绍平[1] 王华庆[1,2] 张会来[1] 赵静[1] 刘霞[1] 

机构地区：[1]天津医科大学肿瘤医院淋巴瘤科,天津市“肿瘤防治”重点实验室,国家肿瘤临床医学研究中心,中美淋巴血液肿瘤诊治中心,天津300060 [2]天津市人民医院肿瘤诊治中心,天津300121

出　　处：《天津医科大学学报》2016年第1期24-27,共4页Journal of Tianjin Medical University

摘　　要：目的:观察复方阿胶浆治疗化疗后骨髓抑制的临床疗效。方法:将92例恶性肿瘤患者随机分为3组,一组为对照组(30例),另两组为高低剂量治疗组(62例)。所有患者均接受常规化疗,两治疗组分别联合复方阿胶浆口服治疗(低剂量组20 m L,3次/d,33例;高剂量组40 m L,3次/d,29例)。治疗42 d期间,观察3组的总体疗效及不良反应。结果:(1)治疗前各组疗效指标无统计学差异。(2)治疗结束,对照组血红蛋白(99.56 g/L±8.29 g/L)与低、高剂量治疗组(109.68 g/L±18.95 g/L、112.95 g/L±19.59 g/L)相比有统计学差异(P<0.05);中医症候评分对照组(11.34±3.55)与低、高剂量治疗组(5.29±2.37、9.48±4.40)比较具有统计学差异(P<0.05)。(3)组内疗效比较,对照组血红蛋白较化疗前减低,下降均值为6.34±1.27;中医症候评分升高,上升均值为4.89±0.56,具有统计学差异(P<0.05)。治疗组化疗前后未见明显差异(P>0.05)。(4)组间疗效比较,高剂量组第28天血红蛋白、红细胞计数、血小板计数分别为(116.95±18.11)g/L、(3.93±0.72)×1012/L、(229.55±80.62)×109/L,均显著高于低剂量组,差异有统计学意义(P<0.05),但白细胞计数无明显差异(P>0.05)。(5)治疗组癌性疲乏较对照组明显减低(32.3%vs 86.7%)。(6)药物不良反应发生率低,主要表现为轻度的便秘、腹泻及胃部不适等。结论:复方阿胶浆可一定程度上改善放化疗相关性贫血,并可提高患者生活质量。Objective： To observe the clinical effect of compound Ejiao Jiang on chemotherapy-induced myelosuppression. Methods： Ninety-two cancer patients were randomly divided into control group （n=30） and treatment group （n=62）, with the latter including low and high dose groups. All patients were given routine chemotherapy, and two treatment groups were additionally given oral compound Ejiao Jiang from 20 mL tid to 40 mL tid. Following the treatment, the changes of RBC,WBC,PLT ,Hgb and the Traditional Chinese Medicine （TCM） symptoms were observed every week. Results： （1）There were no significant differences in clinical indexes among three groups at the beginning.（2）At the end of treatment, Hgb in control group （99.56 g/L±8.29 g/L） showed difference when compared to low and high dose treatment group （109.68 g/L±18.95 g/L, 112.95 g/L±19.59 g/L） （P〈0.05）. The difference was also seen in TCM symptom scores between control group （11.34±3.55 ） and low ＆ high dose group （5.29±2.37, 9.48±4.40） （P〈0.05）. （3）The level of Hgb decreased after the chemotherapy in control group, with the falling mean value of 6.34±1.27 （P〈0.05）; TCM symptom scores were also increased in control group, with the elevating mean value of 4.89±0.56 （P〈0.05）. In contrast, there were no differences in Ejiao Jiang treatment groups. （4）At the 28th day of treatment, the level of Hgb, PLT, RBC in the high dose group was obviously higher than the low dose group （P〈0.05）, but leukocyte showed no difference during treatment （P〉0.05）. （5） The incidence of cancer-related fatigue was lower in treatment group than control group （32.3% vs 86.7% ）. （6） Treatment side effects showed a low incidence, mainly including constipation, diarrhea, and upset stomach. Conclusion： Compound Ejiao Jiang can improve chemotherapy-induced anemia to a certain extent and enhance patients＇ life quality.

关 键 词：骨髓抑制 化疗 复方阿胶浆 癌性疲乏 

分 类 号：R730.5[医药卫生—肿瘤]